Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations. / Khalil, Insaf F; Alifrangis, Michael; Recke, Camilla; Hoegberg, Lotte C; Ronn, Anita; Bygbjerg, Ib C; Koch, Claus.
I: Malaria Journal, Bind 10, 01.01.2011, s. 249.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations
AU - Khalil, Insaf F
AU - Alifrangis, Michael
AU - Recke, Camilla
AU - Hoegberg, Lotte C
AU - Ronn, Anita
AU - Bygbjerg, Ib C
AU - Koch, Claus
PY - 2011/1/1
Y1 - 2011/1/1
N2 - In Central and South America and Eastern and Southern Africa, Plasmodium vivax infections accounts for 71-81% and 5% of malaria cases, respectively. In these areas, chloroquine (CQ) remains the treatment of choice for P. vivax malaria. In addition, CQ has recently proven to be an effective HIV-1 therapeutic agent. There is a dire need to continue monitoring quality of CQ as there is a major influx of substandard and fake formulations into malaria-endemic countries. The use of fake/substandard drugs will result in sub-therapeutic levels endangering the patient and possibly select for parasite resistance. The aim of this study was to develop an inexpensive, simple antibody-based ELISA to measure CQ concentrations in tablets and in plasma.
AB - In Central and South America and Eastern and Southern Africa, Plasmodium vivax infections accounts for 71-81% and 5% of malaria cases, respectively. In these areas, chloroquine (CQ) remains the treatment of choice for P. vivax malaria. In addition, CQ has recently proven to be an effective HIV-1 therapeutic agent. There is a dire need to continue monitoring quality of CQ as there is a major influx of substandard and fake formulations into malaria-endemic countries. The use of fake/substandard drugs will result in sub-therapeutic levels endangering the patient and possibly select for parasite resistance. The aim of this study was to develop an inexpensive, simple antibody-based ELISA to measure CQ concentrations in tablets and in plasma.
U2 - 10.1186/1475-2875-10-249
DO - 10.1186/1475-2875-10-249
M3 - Journal article
C2 - 21864375
VL - 10
SP - 249
JO - Malaria Journal
JF - Malaria Journal
SN - 1475-2875
ER -
ID: 35277189